Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:01 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.87 | 0.88 | -0.99 |
| EPS, GAAP | 0.74 | 0.77 | 0.77 |
| Consensus Estimate | 0.78 | 0.81 | -3.70 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 3.81 | 4.49 | -15.15 |
| EPS, GAAP | 3.66 | 3.90 | -6.24 |
| Consensus Estimate | 3.33 | 4.35 | -23.54 |
| LLY | Industry Average | |
| P/E (TTM) | 15.39 | NA |
| P/E (Forward) | 14.60 | NA |
| PEG Ratio | 0.00 | 2.19 |
| Price/Sales | 2.80 | 18.50 |
| Beta | 0.72 | 0.70 |
| 8:59 AM | 4/2/2013 | Lilly Aims to Spend Added $180 Million to Increase Scope of Indianapolis Insulin Plant Expansion |
| 3:04 PM | 3/25/2013 | CEO Pay Declines at Lilly, Rises at Bristol-Myers |
| 4/4/2013 | The Morning Ledger: Pharma Firms Embrace Pay Clawbacks (WSJ.com) |
| 4/3/2013 | Drug Firms Expand Powers to Recoup Pay (WSJ.com) |
| 3/27/2013 | Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC) (24/7 Wall St) |
| 3/16/2013 | Zoetis: Too Many Folks' Pet Stock (Barrons.com) |
| 3/14/2013 | FDA Opens Safety Review of Diabetes Drugs (WSJ.com) |
| 3/6/2013 | Lilly Says Europe Must Lift Drug Prices (WSJ.com) |
| 3/5/2013 | J&J, Bayer Fail to Gain FDA Approval for Blood Thinner (24/7 Wall St) |
| 2/25/2013 | Pension Strategies Differ as Costs Balloon (WSJ.com) |
